大道制药 2024年度报告

FORM10-K ANNUAL REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the FiscalYear EndedDecember 31, 2024 or (Address of principal executive offices and zip code) (781)652-4500(Registrant’s telephone number, including area code) Securities registered pursuant to Section12(b)of the Act: (1)On March 17, 2025, the Nasdaq Stock Market LLC (“Nasdaq”) notified the Company that Nasdaq had determined to delist theCompany’s common stock and that trading of the Company’s securities would be suspended at the open of trading on March 19,2025. Nasdaq will file a Form 25 with the SEC notifying the SEC of Nasdaq’s determination to remove the Company’s securitiesfrom listing on Nasdaq, at which time the common stock will cease to be registered pursuant to Section 12(b) of the Act andimmediately be deemed registered pursuant to Section 12(g) of the Act. Since March 19, 2025, the Company’s common stock hasbeen traded on the over-the-counter market under the symbol “ATXI”. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule405 of the Securities Act. Yes☐No☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section13 or Section15(d)of the Act. Yes☐No☒ Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of the Securities Exchange Act of 1934during the preceding 12months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filingrequirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T(§232.405 of this chapter) during the preceding 12months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company”in Rule12b-2 of the Exchange Act: Largeacceleratedfiler☐Non-accelerated filer☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new orrevised financial accounting standards provided pursuant to Section13(a)of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal controlover financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issuedits audit report.☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filingreflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received byany of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Act).Yes☐No☒ The aggregate market value of the voting stock held by non-affiliates of the registrant the last business day of the registrant’s most recently completed secondfiscal quarter: $3,910,957. Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date. AVENUE THERAPEUTICS, INC.ANNUAL REPORT ON FORM 10-KTABLE OF CONTENTS PagePART IItem 1.Business4Item 1A.Risk Factors27Item 1B.Unresolved Staff Comments55Item 1C.Cybersecurity55Item 2.Properties55Item 3.Legal Proceedings55Item 4.Mine Safety Disclosures55PART IIItem 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities56Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations57Item 8.Consolidated Financial Statements and Supplementary Data66Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure66Item9A.Controls and Procedures66Item 9B.Other Information66Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections67PART IIIItem 10.Directors, Executive Officers and Corporate Governance67Item 11.Executive Compensation71Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters74Item 13.Certain Relationships and Related Transactions, and Director Independence75Item14.Principal Accountant Fees and Services78PART IVItem15.Exhibits and Consolidated Financial St